Expand ALKS Menu
ALKS MENU

ALKS Latest Press Releases

-- December 12, 2025 --

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL PRNewswire 4:38 PM

-- December 5, 2025 --

Announcement relating to despatch of Rule 15 proposal Globe Newswire 4:01 PM

-- November 25, 2025 --

Alkermes to Participate in Two Upcoming Investor Conferences Business Wire 4:00 PM

-- November 19, 2025 --

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc PRNewswire 6:00 AM

-- November 17, 2025 --

Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal" Globe Newswire 5:45 AM

-- November 14, 2025 --

Alkermes Response to Avadel Announcement PRNewswire 7:45 AM
Avadel Receives Unsolicited Proposal from Lundbeck Globe Newswire 5:45 AM

-- November 12, 2025 --

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 PRNewswire 7:30 AM

-- November 6, 2025 --

Alkermes to Participate in Two Upcoming Investor Conferences PRNewswire 4:00 PM

-- November 5, 2025 --

FORM 8.1(a) & (b) (Opening Position Disclosure) PRNewswire 9:01 AM

-- October 28, 2025 --

Alkermes plc Reports Third Quarter 2025 Financial Results PRNewswire 7:00 AM

-- October 22, 2025 --

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL Business Wire 4:52 PM
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc PRNewswire 7:00 AM

-- October 20, 2025 --

Alkermes to Report Third Quarter Financial Results on October 28, 2025 PRNewswire 4:00 PM

-- September 12, 2025 --

Alkermes Appoints Joshua Reed as Chief Financial Officer PRNewswire 9:00 AM

-- September 11, 2025 --

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards Program PRNewswire 7:00 AM

-- September 8, 2025 --

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 PRNewswire 3:15 AM

-- September 1, 2025 --

Gains prvus pour le 1er septembre 2025 Benzinga Insights 4:32 AM

-- August 25, 2025 --

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 PRNewswire 7:00 AM

-- July 29, 2025 --

Alkermes plc Reports Second Quarter 2025 Financial Results PRNewswire 7:00 AM

-- July 21, 2025 --

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 PRNewswire 6:00 AM

-- July 15, 2025 --

Alkermes to Report Second Quarter Financial Results on July 29, 2025 PRNewswire 4:00 PM
Market Data Delayed 15 Minutes